Low Float (Nasdaq: NTRB) Keeps Cranking After Breaking News (Now Up Approx. 19%)

Nutriband Inc. (Nasdaq: NTRB) keeps on humming early Friday.

*Sponsored by Nutriband Inc. Low Float (Nasdaq: NTRB) Keeps Cranking After Breaking News (Now Up Approx. 19%)  February 7th Dear Reader, Nutriband Inc. (Nasdaq: NTRB) keeps on humming early Friday. Now up approximately 19%, NTRB continues to impress behind today's breaking news. Check it out here: Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™ On top of that, it's important to note that Barchart is reporting 4 triggered technical indicators in the short term for NTRB including its: 20 Day Moving Average 20 - 50 Day MA Crossover 20 - 100 Day MA Crossover 20 - 200 Day MA Crossover Do yourself a favor and take a second to review my initial report and consider (Nasdaq: NTRB) for your radar. ----- Listen. I'm not going to overload you with too many details in this intro, so let me get straight to the important stuff. #1. My most recent profile rocketed approximately 31% intraday Thursday, running from an open of $.57 to a high of $.75. #2. This next profile is a breakout idea and 2X past champ. Most recently, it exploded to a new 52-week high of $11.78 from an after hours close of $5.22 two days earlier. That move? Approximately 125%. #3. A $13 analyst target from January is suggesting substantial upside potential from current levels. Now, imagine a company at the forefront of innovation, pushing boundaries and redefining what's possible in their industry. With groundbreaking technology that could revolutionize patient care, this Biotech company is poised to make a significant impact on global health. As they prepare to unveil their flagship product, anticipation builds for a potential game-changer in the medical field. That's why it may be time to consider this Nasdaq breakout idea for your watchlist: *Nutriband Inc. (Nasdaq: NTRB)* Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Their lead product under development is an abuse-deterrent fent-a-nyl patch incorporating their AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. And based on several potential breakout catalysts, NTRB has risen to the top spot on my watchlist: #1. A $13 Analyst Target Suggests Substantial Upside Potential! #2. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #3. Company's Subsidiary Sees Revenue Pop Off In Q3, Up Approx. 50%! #4. Strong Patent News Could Put NTRB In A Strengthened Position To Defend And Commercialize AVERSA™. But more on those in a second... Full Company Breakdown: Nutriband Inc. (Nasdaq: NTRB) Nutriband Inc. is a pharmaceutical company with a specific focus on transdermal technologies. Their model is to apply Transdermal Tech to existing FDA approved drugs with a goal to improve safety, efficacy, patient comfort and more. The company's first product and lead platform technology is AVERSA, an abuse deterrent tech which is applicable to any patch on the market today. According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl is expected to reach peak annual sales of $200Mn. The company has 2 revenue generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical along with Active Intelligence which specializes in sports recovery products. Nutriband is earning revenues to keep their development burn at a minimum. They also own their own manufacturing and clinical development capabilities which drastically reduces their costs for AVERSA and other technologies. Furthermore, the company believes this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes. AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids Upon approval of AVERSA™ fent-a-nyl, the company expects that the FDA will consider requiring all fent-a-nyl patches be abuse deterrent as was required for all Oxy-con-tin generics Pipeline products include AVERSA™ buprenorphine and AVERSA™ meth-yl-phenidate According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl will be priced competitively with generic fent-a-nyl patches and is expected to reach peak annual sales of $200Mn. If non-ADF transdermal fent-a-nyl products lose marketing approval, Aversa would have greater pricing flexibility and could generate >$800Mn in revenue. Aversa Pipeline Sources: NTRB Website. NTRB Presentation. ----- As mentioned above, NTRB has several potential catalysts that could create breakout buzz. Here's a few to consider now: #1. NTRB Potential Catalyst - A $13 Analyst Target Suggests Substantial Upside Potential! Last month, an analyst Noble Capital Markets provided NTRB with a $13 target. At the time, it suggested over 100% potential upside from that previous valuation. Here's some key report highlights: We Are Initiating Coverage With An Outperform Rating. Nutriband, Inc. is a pharmaceutical company developing transdermal patch technologies for drug delivery. Its proprietary technology, known as AVERSA, has abuse-deterrent features with important differences from other transdermal patches on the market. The lead product is AVERSA Fent-a-nyl, an abusedeterrent transdermal patch for delivering fent-a-nyl that improves safety, compliance, and patient comfort. Conclusion. We believe the Phase 1 clinical trial will show sufficient abuse deterrence to allow for Nutriband to file a New Drug Application using the 505(b)(2) pathway for approval in 2H25. We have allowed for a 10-month standard review, although Priority Review could potentially shorten review time to 6 months. We anticipate approval in 2H26. We base our valuation on FY2027 EPS of $1.45 per share discounted at 30% per year and apply a multiple of 15X for a price target of $13 per share. ----- #2. NTRB Potential Catalyst - A Low Float Could Create An Exceptionally Volatile Environment (Daily). According to info from the Yahoo Finance website, NTRB has a pretty low float. The website reports this profile to have roughly 5.05Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could positive company news early in 2025 provide a breakout spark? ----- #3. NTRB Potential Catalyst - Company's Subsidiary Sees Revenue Pop Off In Q3, Up Approx. 50%! Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fent-a-nyl in 2025 ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its fi-nan-cial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fent-a-nyl, with an NDA submission targeted for first half of 2025. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain a foothold with some of the industry’s largest brands. The Company produced a record third quarter reporting revenue of $645k+ USD, up 50.94% YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS. Progress continues on the development of AVERSA Fent-a-nyl, with the Company maintaining its goal of submitting an NDA to the FDA in the first half of 2025. Nutriband recently updated shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before submission. If approved, AVERSA Fent-a-nyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fent-a-nyl is estimated to have the potential to reach peak annual sales of $80-$200Mn, according to a market analysis report from Health Advances. AVERSA Buprenorphine, which is the company’s second application for AVERSA, is projected to reach peak annual sales of up to $130Mn. ... Read the full article here. ----- #4. NTRB Potential Catalyst - Strong Patent News Could Put NTRB In A Strengthened Position To Defend And Commercialize AVERSA™. A handful of positive patent-related press releases have popped up in the last few months. Take a look: 12/27/24 - Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology 11/27/24 - Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology 10/31/24 - Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application These developments strengthen NTRB's ability to defend and commercialize AVERSA™ globally, setting the stage for Nutriband to become the leader in abuse-deterrent technology. ----- (Nasdaq: NTRB) Potential Catalyst Recap - The Top 4 To Consider Right Now #1. A $13 Analyst Target Suggests Substantial Upside Potential! #2. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #3. Company's Subsidiary Sees Revenue Pop Off In Q3, Up Approx. 50%! #4. Strong Patent News Could Put NTRB In A Strengthened Position To Defend And Commercialize AVERSA™. ----- Coverage is officially reinitiated on Nutriband Inc. (Nasdaq: NTRB). I'll be in touch with updates when necessary. Talk again soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/06/25 and ending on 02/07/25 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, SWN Media LLC was paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid seventy-five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither SWN Media LLC or its member own shares of (NTRB:US). Please see important disclosure information here: https://www.fierceanalyst.net/disclosure/ntrb/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice